公开(公告)号：US20240269304A1

公开(公告)日：2024-08-15

申请号：US18038435

申请日：2021-11-23

Applicant: Novartis AG ,  Les Laboratoires Servier

Inventor： Matthew T. Burger ,  Zhuoliang Chen ,  Joseph Anthony D'Alessio ,  Eric McNeill ,  Katsumasa Nakajima ,  Richard Vaughan Newcombe ,  Mark G. Palermo ,  Bing Yu ,  Qiang Zhang ,  Frédéric Colland ,  James Edward Paul Davidson ,  Lea Delacour ,  Patrice Desos ,  Olivier Geneste ,  Vesela Kostova ,  Andras Kotschy ,  Ana Leticia Maragno ,  James Brooke Murray ,  Tibor Novak ,  Jérôme Benoit Starck

IPC: A61K47/68 ,  A61P35/00

CPC classification number: A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6889 ,  A61P35/00

Abstract: Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a Bcl-xL inhibitor drug moiety. The disclosure farther relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making same are also disclosed.

公开(公告)号：US11999786B2

公开(公告)日：2024-06-04

申请号：US17534126

申请日：2021-11-23

Applicant: Novartis AG

Inventor： Joseph Anthony D'Alessio ,  Claudia Judith Klinter ,  Cornelia Anne Mundt ,  Richard Vaughan Newcombe ,  Tamás Schweighoffer ,  Katharina Winkelbach

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68

CPC classification number: C07K16/2803 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  C07K2317/565 ,  C07K2317/92

Abstract: Disclosed herein are antibodies, antigen binding fragments thereof, and antibody drug conjugates thereof that bind human CD48. Also disclosed are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, and antibody drug conjugates thereof; and methods of making and using such pharmaceutical compositions for treating cancer in a patient in need of treatment.

公开(公告)号：US20240042051A1

公开(公告)日：2024-02-08

申请号：US18038437

申请日：2021-11-23

Applicant: Francesca Rocchetti ,  Novartis AG

Inventor： Matthew T. Burger ,  Zhuoliang Chen ,  Joseph Anthony D'Alessio ,  Claudia Judith Klinter ,  Eric McNeill ,  Cornelia Anne Mundt ,  Katsumasa Nakajima ,  Richard Vaughan Newcombe ,  Mark G. Palermo ,  Tamas Schweighoffer ,  Bing Yu ,  Katharina Winkelbach ,  Qiang Zhang ,  Laura Bresson ,  Frédéric Colland ,  Ana Leticia Maragno ,  Francesca Rocchetti

IPC: A61K47/68 ,  A61P35/00

CPC classification number: A61K47/6867 ,  A61K47/6889 ,  A61P35/00 ,  A61K47/6803

Abstract: Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.